Financials data is unavailable for this security.
View more
Year on year Glycorex Transplantation AB (publ) 's revenues fell -17.04% from 36.12m to 29.96m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 8.58m to a larger loss of 30.36m.
| Gross margin | 82.91% |
|---|---|
| Net profit margin | -89.70% |
| Operating margin | -88.71% |
| Return on assets | -36.96% |
|---|---|
| Return on equity | -53.31% |
| Return on investment | -46.32% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at Glycorex Transplantation AB (publ) fell by 19.74m. Cash Flow from Investing was negative at 3.55m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 9.46m for operations while cash used for financing totalled 6.63m.
| Cash flow per share | -0.085 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.5186 |
|---|---|
| Tangible book value per share | 0.2361 |
More ▼
Balance sheet in SEKView more
| Current ratio | 1.51 |
|---|---|
| Quick ratio | 1.09 |
| Total debt/total equity | 0.2633 |
|---|---|
| Total debt/total capital | 0.2084 |
More ▼
Growth rates in SEK
Year on year, growth in earnings per share excluding extraordinary items dropped -254.06%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -152.29 |
